脑出血发病率、死亡率及与口服抗凝药使用的关联:一项人群研究
研究期间住院死亡率和1年死亡率分别下降10.4%和7.6%。口服抗凝药使用与住院死亡(调整OR 1.37,95%CI 1.26-1.49)和1年死亡(HR 1.18,95%CI 1.12-1.25)相关。
要点
- 脑出血总体发病率为19.1/100 000人年,研究期间无显著变化。
- 住院死亡率32.4%,1年死亡率45.4%,2年死亡率49.5%。
- 口服抗凝药使用与住院及1年死亡风险升高相关。
核心结论
- 过去十年脑出血短期和长期死亡率均下降。
- 口服抗凝药使用与脑出血后短期和长期死亡率相关。
主要发现
- 平均(SD)年龄71.3(15.1)岁,52.6%为男性。
- 总体发病率为19.1/100 000人年,研究期间无明显变化。
- 住院死亡率为32.4%,1年死亡率为45.4%,2年死亡率为49.5%。
- 仅14.5%患者独立出院回家。
- 研究期间住院死亡率下降10.4%(37.5%至27.1%,P<0.001),1年死亡率下降7.6%(50.0%至42.4%,P<0.001)。
关键数值与推荐
- 口服抗凝药使用与住院死亡相关(调整OR 1.37,95%CI 1.26-1.49)。
- 口服抗凝药使用与1年死亡相关(HR 1.18,95%CI 1.12-1.25)。
临床怎么用
- 脑出血后死亡率高,多数幸存者需长期护理,应加强急性期和长期管理。
- 使用口服抗凝药者发生脑出血后死亡风险更高,临床决策需权衡抗凝获益与出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Spontaneous intracerebral hemorrhage (ICH) is a devastating form of stroke associated with significant morbidity and mortality. Recent epidemiological data on incidence, mortality, and association with oral anticoagulation are needed. METHODS: Retrospective cohort study of adult patients (≥18 years) with ICH in the entire population of Ontario, Canada (April 1, 2009-March 30, 2019). We captured outcome data using linked health administrative databases. The primary outcome was mortality during hospitalization, as well as at 1 year following ICH. RESULTS: We included 20 738 patients with ICH. Mean (SD) age was 71.3 (15.1) years, and 52.6% of patients were male. Overall incidence of ICH throughout the study period was 19.1/100 000 person-years and did not markedly change over the study period. In-hospital and 1-year mortality were high (32.4% and 45.4%, respectively). Mortality at 2 years was 49.5%. Only 14.5% of patients were discharged home independently. Over the study period, both in-hospital and 1-year mortality reduced by 10.4% (37.5% to 27.1%, P<0.001) and 7.6% (50.0% to 42.4%, P<0.001), respectively. Use of oral anticoagulation was associated with both in-hospital mortality (adjusted odds ratio 1.37 [95% CI, 1.26-1.49]) and 1-year mortality (hazard ratio, 1.18 [95% CI, 1.12-1.25]) following ICH. CONCLUSIONS: Both short- and long-term mortality have decreased in the past decade. Most survivors from ICH are likely to be discharged to long-term care. Oral anticoagulation is associated with both short- and long-term mortality following ICH. These findings highlight the devastating nature of ICH, but also identify significant improvement in outcomes over time.
引用
- Fernando SM, Qureshi D, Talarico R, et al. Intracerebral Hemorrhage Incidence, Mortality, and Association With Oral Anticoagulation Use: A Population Study. Stroke. 2021. PMID: 33685222. doi:10.1161/STROKEAHA.120.032550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。